Clinical trial · no report yet · Phase 3
LIGHTHOUSE
Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma
- NCT04649060 ↗
- Terminated
- Oncopeptides AB
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in Combination With Daratumumab Compared With Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Relapsed Multiple Myeloma; Relapsed-Refractory Multiple Myeloma
- Interventions
- Melflufen; Dexamethasone; Daratumumab
- Arms
- Arm A (melflufen+dexamethasone+daratumumab) · Experimental
- Arm B (daratumumab) · Active comparator
- Enrollment
- 54
- Primary outcomes
- Progression Free Survival (PFS)
- Sponsor
- Oncopeptides AB
- Start
- Dec 21, 2020
- Primary completion
- Feb 7, 2022
- Results posted
- Yes
- Registry record
- NCT04649060 · updated Jun 8, 2023
Publications
linked from the registry- Pour L, Szarejko M, Bila J, Schjesvold FH, Spicka I, Maisnar V, Jurczyszyn A, Grudeva-Popova Z, Hajek R, Usenko G, Thuresson M, Norin S, Jarefors S, Bakker NA, Richardson PG, Mateos MV. Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study. Haematologica. 2024 Mar 1;109(3):895-905. doi: 10.3324/haematol.2023.283509. PubMed 37646660
- Ocio EM, Efebera YA, Hajek R, Straub J, Maisnar V, Eveillard JR, Karlin L, Mateos MV, Oriol A, Ribrag V, Richardson PG, Norin S, Obermuller J, Bakker NA, Pour L. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study. Haematologica. 2024 Mar 1;109(3):867-876. doi: 10.3324/haematol.2023.283490. PubMed 37646657